Login to Your Account



Regeneron and Sanofi Begin 'ODYSSEY' for Cholesterol mAb

By Catherine Shaffer
Staff Writer

Monday, July 23, 2012
Sanofi SA and Regeneron Pharmaceuticals Inc. began enrolling patients for several trials within its Phase III program for REGN727, an antibody for lowering LDL cholesterol.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription